Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c, FY Guidance Beats
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $79.45 +3.17%
EPS Growth %: +17.5%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $59.77 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $168.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Rivian raises 2026 delivery outlook after Q2 results top guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
